Lead Product(s) : SkinTE
Therapeutic Area : Podiatry
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data show a statistically significant difference favoring PolarityTE’s autologous skin construct, SkinTE, in the primary endpoint of wounds closed at 12 weeks, and in percent area reduction of wounds at each time point measured.
Product Name : SkinTE
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 24, 2020
Lead Product(s) : SkinTE
Therapeutic Area : Podiatry
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable